VASONIT RETARD PILLS 600MG
VASONIT RETARD PILLS 600MG - 20 tabs
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Coated Extended Release Tablets
1 pill contains Pentoxifylline 600 mg;
Excipients: hypromellose 15000 mPa * s, microcrystalline cellulose, crosspovidone, colloidal silicon dioxide, Magnesium stearate.
shell composition: macrogol 6000, hypromellose 5 mPa * s, anti-foam agent SE2 MK silicon, titanium dioxide, talc, polyacrylate dispersion 30%.
Mechanism of action
Antispasmodic from the group of purines. Vasonit improves microcirculation and rheological properties of blood, inhibits PDE, increases the concentration of cAMP in platelets and ATP in erythrocytes with simultaneous saturation of the energy potential, which in turn leads to vasodilation, a decrease in CRPS, an increase in ASI and IOC without a significant change in heart rate. Expanding the coronary arteries, increases the delivery of oxygen to the myocardium (antianginal effect), the vessels of the lungs - improves blood oxygenation. Increases the tone of the respiratory muscles (intercostal muscles and diaphragm).
Indications and usage
Peripheral circulatory disorders (intermittent claudication on the background of diabetic angiopathy, obliterating endarteritis), Raynaud’s disease, tissue trophic disorders (post-thrombotic syndrome, varicose veins, trophic ulcers of the leg, gangrene, frostbite); disorders of cerebral circulation: ischemic and postapoplexic conditions; cerebral atherosclerosis (dizziness, memory disorders, sleep disorders), dyscirculatory encephalopathy, viral neuroinfection (prevention of possible microcirculation disorders); IHD, condition after myocardial infarction; acute circulatory disorders in the retina and choroid; otosclerosis, degenerative changes on the background of the pathology of the vessels of the inner ear with a gradual decrease in hearing; COPD, bronchial asthma; impotence of vascular genesis.
Hypersensitivity to pentoxifylline, etc.xanthine derivatives; acute myocardial infarction; porphyria, massive bleeding, hemorrhagic stroke, retinal hemorrhage, pregnancy, lactation. With caution. Lability of BP (tendency to hypotension), CHF, gastric ulcer and 12 duodenal ulcer (for ingestion), condition after recently undergone surgical interventions, hepatic and / or renal failure, age up to 18 years (efficacy and safety have not been studied).
Pregnancy and Breastfeeding
The use of the drug Vasonit during pregnancy is contraindicated. If necessary, the use of the drug during lactation should stop breastfeeding.
Dosage and administration
The enteric pills are swallowed whole with a small amount of water. The daily dose is divided into 3 doses. The initial dose is 600 mg / day. As the state improves, the dose can be reduced to 300 mg / day. Prolonged dosage forms prescribed 2-3 times a day.
Gastrointestinal: possibly nausea, vomiting, diarrhea, dry mouth, loss of appetite, feeling of fullness in the abdomen, epigastric pain, increased activity of liver enzymes (ALT, AST, LDH) and alkaline phosphatase, cholecystitis, hepatitis, jaundice; rarely - an unpleasant taste in the mouth, hypersalivation.
From the side of the central nervous system: relatively rarely - headache, dizziness, anxiety, sleep disturbances, convulsions.
Special senses: rarely - conjunctivitis, scotoma, blurred vision, earache.
Cardiovascular: with the use of the drug in high doses, a decrease in blood pressure, tachycardia, angina, heart rhythm disturbances, flushing of the skin of the face, blood flushes to the skin of the face and upper chest, edema are possible.
Allergic reactions: possible - itching, skin rash, urticaria, angioedema; rarely - anaphylactic shock.
From the hematopoietic system and hemostasis: rarely - bleeding (from the vessels of the stomach, intestines, skin and mucous membranes), thrombocytopenia, leukopenia, pancytopenia, hypofibrinogenemia, changes in the pattern of peripheral blood, aplastic anemia. In this regard, it is necessary to conduct regular monitoring of the blood picture.
Other: rarely - malaise, increased fragility of the nails, changes in body weight, nasal congestion.
Treatment should be under the control of blood pressure. In diabetic patients taking hypoglycemic drugs, the appointment in large doses can cause severe hypoglycemia (dose adjustment is required). When administered simultaneously with anticoagulants, it is necessary to carefully monitor blood coagulation parameters. In patients who have recently undergone surgery, systematic monitoring of Hb and hematocrit is necessary. The dose should be reduced in patients with low and unstable blood pressure. Older people may need to reduce the dose (increased bioavailability and reduced rate of excretion). The safety and efficacy of pentoxifylline in children is not well understood. Tobacco smoke can reduce the therapeutic efficacy of the drug. The compatibility of the pentoxifylline solution with the infusion solution should be checked in each particular case.
Pentoxifylline may enhance the effect of drugs affecting the blood coagulation system (indirect and direct anticoagulants, thrombolytics), antibiotics (including cephalosporins - cefamandol, cefeperazone, cefotetan), valproic acid. Increases the effectiveness of antihypertensive drugs, insulin and oral hypoglycemic drugs. Cimetidine increases the concentration of pentoxifylline in plasma (the risk of side effects). Joint appointment with other xanthines can lead to excessive nervous excitement of patients.
Symptoms: nausea, dizziness, decrease in blood pressure, fever (chills), tachycardia, drowsiness or agitation, loss of consciousness, areflexia, tonic-clonic convulsions, vomiting like "coffee grounds" (as a sign of gastrointestinal bleeding), arrhythmias are possible.
Treatment: gastric lavage, further symptomatic therapy. The specific antidote is absent. In the case of vomiting with traces of blood, gastric lavage is unacceptable.
The drug should be stored in a dry, protected from light, out of reach of children at a temperature not exceeding 25 ° C.